|
|
R Simantov, J M LaSala, S K Lo, A E Gharavi, L R Sammaritano, J E Salmon, R L Silverstein
J Clin Invest. 1995;
96(5):2211
doi:10.1172/JCI118276
Abstract |
Full text
| PDF

C
irculating antiphospholipid antibodies (aPL) are associated with a syndrome of thrombosis, recurrent fetal loss, and thrombocytopenia. We have demonstrated the activation of cultured human umbilical vein endothelial cells (HUVEC) by IgG from patients with anticardiolipin antibodies (aCL). Incubation of HUVEC for 4 h with purified IgG (100 micrograms/ml) from patients with high-titer aCL induced a 2.3-fold increase in monocyte adhesion over that seen in HUVEC incubated with IgG's from normal subjects. The effect of aCL was not attributable to LPS contamination, Fc receptors, or immune complexes. Monocyte adhesion was not induced when the aCL were added in serum-free media but was restored by the addition of purified beta 2GP1, previously described as a necessary cofactor for aCL reactivity. Purified rabbit polyclonal IgG raised against beta 2GP1 also induced monocyte adhesion when incubated with HUVEC. Preadsorption of patient serum with cardiolipin reduced monocyte adhesion by 60%. Immunofluorescent microscopy demonstrated that endothelial cells incubated with patient IgG expressed cell adhesion molecules, including E-selectin, vascular cell adhesion molecule-1, and intracellular adhesion molecule-1. These data support the hypothesis that aPL activate vascular endothelial cells, thereby leading to a pro-thrombotic state.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(119)
| Title and authors |
Publication |
Year |
A novel pathway for human endothelial cell activation by antiphospholipid/anti- 2 glycoprotein I antibodies
K. L. Allen, F. V. Fonseca, V. Betapudi, B. Willard, J. Zhang, K. R. McCrae
|
Blood
|
2012 |
Endothelial cell activation by antiphospholipid antibodies is modulated by Kruppel-like transcription factors
K. L. Allen, A. Hamik, M. K. Jain, K. R. McCrae
|
Blood
|
2011 |
Evidence for heterogeneity of the obstetric antiphospholipid syndrome: thrombosis can be critical for antiphospholipid-induced pregnancy loss : Heterogeneity of obstetric antiphospholipid syndrome
V. POINDRON, R. BERAT, A. M. KNAPP, F. TOTI, F. ZOBAIRI, A. S. KORGANOW, M. P. CHENARD, C. GOUNOU, J. L. PASQUALI, A. BRISSON
|
Journal of Thrombosis and Haemostasis
|
2011 |
Serum autoantibody biomarkers for age-related macular degeneration and possible regulators of neovascularization
Kei Morohoshi, Nishal Patel, Masaharu Ohbayashi, Victor Chong, Hans E. Grossniklaus, Alan C. Bird, Santa J. Ono
|
Experimental and Molecular Pathology
|
2011 |
ANTIPHOSPHOLIPID SYNDROME
Tadej Avčin, Kathleen M. O’Neil
|
Textbook of Pediatric Rheumatology
|
2011 |
Anticorps antiphospholipides et hémostase
J. Masliah-Planchon, L. Darnige
|
La Revue de Médecine Interne
|
2011 |
Antiphospholipid Syndrome
Tatsuya Atsumi, Olga Amengual, Takao Koike
|
Systemic Lupus Erythematosus
|
2011 |
Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome
Z. Romay-Penabad, R. Aguilar-Valenzuela, R. T. Urbanus, R. H. W. M. Derksen, M. T. T. Pennings, E. Papalardo, T. Shilagard, G. Vargas, Y. Hwang, P. G. de Groot, S. S. Pierangeli
|
Blood
|
2010 |
Antibodies to Serine Proteases in the Antiphospholipid Syndrome
Pojen P. Chen, Ian Giles
|
Curr Rheumatol Rep
|
2010 |
Neurological manifestations of antiphospholipid syndrome
Carlos E. M. Rodrigues, Jozélio F. Carvalho, Yehuda Shoenfeld
|
European Journal of Clinical Investigation
|
2010 |
|